Literature DB >> 9657523

Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF, and FAKpp125.

A Ahmed1, S Dearn, M Shams, X F Li, R K Sangha, M Rola-Pleszczynski, J Jiang.   

Abstract

Implantation is characterized by an inflammatory-like response with expansion of extracellular fluid volume, increased vascular permeability, and vasodilatation. These effects are believed to be mediated at the paracrine level by prostaglandin E2 and platelet-activating factor (PAF), but the cellular mechanism (or mechanisms) remains largely unknown. We demonstrate that PAF receptor (PAF-R) immunoreactivity and mRNA are detected in proliferative and secretory endometrial glands, however, the responsiveness of endometrium to physiological concentrations of PAF is confined predominantly to the secretory endometrium. Semiquantitative reverse transcription-polymerase chain reaction revealed that PAF-R transcript levels were highest in the mid-late proliferative and late secretory phases of the cycle. Interaction of PAF with its receptor resulted in the rapid release of nitric oxide (NO), increased expression of vascular endothelial growth factor (VEGF), and activation of FAKpp125, a focal adhesion kinase, demonstrating that the PAF-R is functionally active. Inhibition of NO synthesis by NG-monomethyl-L-arginine produced dose-dependent attenuation of PAF-evoked NO release, indicating NOS activation; the dependency of PAF-evoked NO release on PKC and extracellular Ca2+ was confirmed by PKC inhibitor Ro 31-8220 and by the removal of extracellular Ca2+. PAF up-regulated VEGF gene expression in a concentration- and time-dependent fashion in human endometrial epithelial cell lysates. Transcription of VEGF was rapidly followed by secretion of the protein. These data support our premise that this autocoid acts as an angiogenic mediator in the regeneration of the endometrium after menses and as a vasodilator to promote blastocyst attachment during the implantation process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657523     DOI: 10.1096/fasebj.12.10.831

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

Review 1.  Macular oedema: the role of soluble mediators.

Authors:  D Kent; S A Vinores; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

Review 2.  Nitric oxide and its role in blastocyst implantation.

Authors:  Omid Khorram
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

3.  PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer.

Authors:  Lei Sun; Zhen He; Jia Ke; Senmao Li; Xianrui Wu; Lei Lian; Xiaowen He; Xiaosheng He; Jiancong Hu; Yifeng Zou; Xiaojian Wu; Ping Lan
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 4.  The multifactorial nature of retinal vascular disease.

Authors:  Mark E Kleinman; Judit Z Baffi; Jayakrishna Ambati
Journal:  Ophthalmologica       Date:  2010-08-18       Impact factor: 3.250

Review 5.  Diverse roles of prostaglandins in blastocyst implantation.

Authors:  Naguib Salleh
Journal:  ScientificWorldJournal       Date:  2014-01-27

6.  Lipopolysaccharide induces nitric oxide synthase expression and platelet-activating factor increases nitric oxide production in human fetal membranes in culture.

Authors:  Gunter Seyffarth; Paul N Nelson; Simon J Dunmore; Nalinda Rodrigo; Damian J Murphy; Ray J Carson
Journal:  Reprod Biol Endocrinol       Date:  2004-06-10       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.